BSE filing, NSE: MARKSANS. Summary written from the filing by ALFA Finder's alert engine.
Marksans Pharma Ltd: key numbers
- Share price
- ₹304.75
- Market cap
- ₹13,810 Cr
- Revenue (annual)
- ₹2,951 Cr
- Net profit (annual)
- ₹417.9 Cr
- P/E (TTM)
- 26.7×Sector 46.5×
- Promoter holding
- 43.87%+0.00% QoQ
- FII holding
- 19.06%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Marksans Pharma Ltd
All →Marksans Pharma Other Announcement
Periodic quarterly shareholding pattern filing for Marksans Pharma Ltd. This document provides the latest breakdown of shareholder categories as mandated by SEBI.
Marksans Pharma Promoter Selling (Off-Market)
Director Sandra Saldanha gifted 2,28,273 shares of Marksans Pharma Ltd to her daughters in an off-market transaction. This internal transfer reallocates promoter-group equity holdings.
Marksans Pharma Other Announcement
Marksans Pharma intimated shareholders about SEBI's extended special window (Feb 2026–Feb 2027) for re-lodgement of pre-April-2019 physical share transfer deeds. No new business, capital, or operational event is disclosed.
Marksans Pharma Annual General Meeting
Marksans Pharma Limited conducted its 34th Annual General Meeting on August 27, 2026. Shareholders considered the adoption of FY2025-26 financial statements and a dividend of Rs. 0.90 per share.
Marksans Pharma Other Announcement
Marksans Pharma Ltd. has received an ESG score of 56 from Crisil ESG Ratings & Analytics Ltd for Fiscal 2026.
Marksans Pharma Investor Presentation: Key Takeaways
Strong Q1FY27 performance driven by European growth and acquisitions. Marksans achieved highest-ever quarterly EBITDA and PAT, while crossing INR1,000 Cr cash balance.
- Call
- Guides 20% growth
Other board meeting date announcements
All →Jetking Infotrain Board Meeting Date
Jetking Infotrain has scheduled a board meeting on November 4, 2026 to consider unaudited quarterly and half-year results. The trading window remains closed until 48 hours after the results announcement.
Metropolis Healthcare Board Meeting Date
Metropolis Healthcare intimated a board meeting on November 3, 2026 to consider Q2 and half-year unaudited results and possible interim dividend. Trading window is closed October 1 to November 5, 2026.
Aelea Commodities Board Meeting Date
Aelea Commodities has scheduled a board meeting for 2 November 2026 to consider half-year results and other items. The agenda includes an additional independent director, a director resignation, and business expansion and capex.
R Systems International Board Meeting Date
R Systems International will hold a board meeting on 3 November 2026 to consider quarterly and nine-month results to September 2026. The trading window remains closed until 48 hours after the results are declared.
Onida Electronics Board Meeting Date
Onida Electronics schedules a 3 November 2026 board meeting for Q2 and half-year results and ESOP share allotment. Trading window stays closed until 48 hours post-results.
Platinum Industries Board Meeting Date
Platinum Industries Ltd intimated a board meeting on November 4, 2026 to approve unaudited standalone and consolidated results for the quarter and half year ended September 30, 2026. Trading window closed from October 1, 2026.